Alfuzosin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Alfuzosin
- Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Alfuzosin is a selective alpha-1 adrenergic blocker, generally used for urinary symptoms of benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but there are 0 clinical trials and 0 publications supporting this direction. The prediction is model-only and has no pharmacological rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Benign prostatic hyperplasia (from general pharmacology; the SAHPRA record in the Evidence Pack has no indication text) |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 99.9994% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on general knowledge, alfuzosin is a selective alpha-1 adrenergic antagonist. It relaxes smooth muscle in the prostate and bladder neck, which is the basis for its use in BPH.
This prediction is not pharmacologically plausible. Alfuzosin has no known role in hair follicle regulation. Hypertrichosis linked to drugs is typically seen with vasodilators or potassium channel openers such as minoxidil, not with alpha-1 blockade. Ambras syndrome is a rare congenital disorder of hair growth, and no link to alpha-1 adrenergic signalling has been identified.
The very high TxGNN score most likely reflects proximity in the knowledge graph among hair-related phenotypes. It does not reflect a real therapeutic rationale. A score this high should not be read as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered (ClinicalTrials.gov, ICTRP, SANCTR or PACTR entries were not found in the Evidence Pack).
Literature Evidence
Currently no related literature available for this drug and indication.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 41/5.2/0740 | Alfuwin XL | Tablet (oral) |
| Reg. No. A40/5.2/0392 | Rantral MR | Tablet (oral) |
The approved indication text and manufacturer were not captured for either registration. Please check the SAHPRA-approved Professional Information (PI). Essential Medicines List (EML) status was not assessed in the data provided.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug interaction records were found in the query. As a class effect, alpha-1 blockers can cause hypotension, so this would be an important consideration in any new population.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (L5). No trials or literature support it, and no mechanistic link to alpha-1 blockade has been identified. A congenital hair disorder is also a poor fit for a symptomatic drug developed for adult urological use.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications, approved indication), which is currently a blocking data gap
- Mechanism of action data from DrugBank
- Any preclinical or clinical evidence linking alpha-1 adrenergic signalling to hair follicle biology
Other predictions in this pack: The other nine predicted indications are also L5 with no trial support. Nine are “Hold”. Persistent fetal circulation syndrome (rank 8) is labelled “Research Question” only. It has weak biological plausibility, but neonatal hypotension would be a major safety concern. The 20 papers retrieved for the periodontal malformation syndrome (rank 3) are general periodontitis literature and do not mention alfuzosin.
This report is for research reference only and does not constitute medical advice. Any repurposing candidate requires clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.